Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols
BACKGROUND: Cancer clinical trials often employ exclusion criteria that can impact vulnerable populations, particularly individuals with psychological, psychiatric, or neurological conditions.
AIMS: This study aimed to analyze the prevalence and nature of exclusion criteria in clinical trials for prostate, breast, and lung cancers.
METHODS: The EU Clinical Trials Register identified 51 protocols uploaded between 2022 and 2024. Thematic content analysis categorized exclusion criteria, and the justifications provided, while frequency analysis quantified their prevalence.
RESULTS: After excluding five protocols (two non-English and three inaccessible), the final dataset comprised 46 protocols: 13 for prostate cancer (22.8%), 24 for breast cancer (42.1%), and 9 for lung cancer (15.8%). Exclusion criteria targeting vulnerable populations were present in 78.3% of protocols, categorized into five themes: psychiatric conditions (24.6%), neurological conditions (22.8%), other psychological conditions (22.8%), legal/guardianship status (5.3%), and unspecified conditions (24.6%). Compliance concerns (39.1%) were the most common justification, followed by informed consent challenges (32.6%), safety risks (13%), drug interference (10.9%), and not in the best interest (4.3%). Notably, 29.1% of protocols lacked justification for exclusions, raising ethical and transparency concerns.
CONCLUSIONS: The exclusion of vulnerable populations may limit the inclusivity and generalizability of cancer research. Heuristic biases and systemic practices can potentially influence this. Exploring the role of these factors and considering adaptive trial designs, along with providing detailed justifications for exclusion criteria, could support more equitable and representative clinical research.
CMAJ. 2025 May 11;197(18):E497-E505. doi: 10.1503/cmaj.250167.ABSTRACTBACKGROUND: In 2016, the College of Physicians and Surgeons of British Columbia released a legally enforceable opioid prescribing practice standard...
Actas Esp Psiquiatr. 2025 May;53(3):526-534. doi: 10.62641/aep.v53i3.1722.ABSTRACTBACKGROUND: Mild cognitive impairment (MCI) is a critical stage in the development of Alzheimer's disease, and early intervention in...
Actas Esp Psiquiatr. 2025 May;53(3):616-620. doi: 10.62641/aep.v53i3.1813.ABSTRACTPoor adherence to antipsychotic treatment is the main reason for relapse and admission in patients with severe mental illness...
Actas Esp Psiquiatr. 2025 May;53(3):570-577. doi: 10.62641/aep.v53i3.1823.ABSTRACTBACKGROUND: Schizophrenia (SCZ) is a chronic mental disorder characterized by severe impairments in the daily functioning and social interactions...
Actas Esp Psiquiatr. 2025 May;53(3):605-615. doi: 10.62641/aep.v53i3.1830.ABSTRACTOBJECTIVE: To explore the incidence of alcohol use disorder (AUD) after bariatric surgery and the associated risk factors and...
